Accueil > Actualité
Actualite financiere : Actualite bourse

Merck: Keytruda fails twice in phase 3 trials

(CercleFinance.com) - Merck announced on Wednesday that two clinical trials of its cancer drug Keytruda have failed, a setback that could raise questions about the potential for new indications for this flagship immunotherapy.


The US biopharmaceutical company this morning said that a first phase 3 trial had failed to meet its two primary endpoints, including improved survival in treated patients.

The trial - called Keynote-921 - evaluated the combination of Keytruda and chemotherapy in patients with castration-resistant prostate cancer.

Another phase 3 clinical trial, this one of Keytruda, in combination with Eisai's Lenvima, also failed to meet its overall survival and progression-free survival endpoints in non-operable hepatocellular carcinoma, a liver cancer.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.